During the past decade, Peking University People's Hospital conducted 394 clinical trials. In the 10-year time frame, 394 clinical trials started and 35 clinical trials were completed, i.e. on average, 8.9% percent of trials that started reached the finish line to date. In the past 5 years, 219 clinical trials started and 22 clinical trials were completed. i.e. 10% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Peking University People's Hospital" #1 sponsor was "Peking University People's Hospital" with 161 trials, followed by "Hoffmann-La Roche" with 15 trials sponsored, "Nanfang Hospital of Southern Medical University" with 12 trials sponsored, "Celgene" with 10 trials sponsored and "Eli Lilly and Company" with 10 trials sponsored. Other sponsors include 260 different institutions and companies that sponsored additional 143 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Peking University People's Hospital" #1 collaborator was "Peking University People's Hospital" with 28 trials as a collaborator, "Peking Union Medical College Hospital" with 14 trials as a collaborator, "Peking University First Hospital" with 14 trials as a collaborator, "Peking University" with 11 trials as a collaborator and "Beijing Hospital" with 10 trials as a collaborator. Other collaborators include 586 different institutions and companies that were collaborators in the rest 335 trials.

According to Clinical.Site data, the most researched conditions in "Peking University People's Hospital" are "Rheumatoid Arthritis" (17 trials), "Breast Cancer" (10 trials), "Breast Neoplasms" (8 trials), "Carcinoma" (8 trials) and "Multiple Myeloma" (8 trials). Many other conditions were trialed in "Peking University People's Hospital" in a lesser frequency.

Most popular intervention types in "Peking University People's Hospital" are "Drug" (292 trials), "Other" (47 trials), "Procedure" (44 trials), "Device" (34 trials) and "Biological" (24 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (60 trials), "Atezolizumab" (6 trials), "Dexamethasone" (6 trials), "Zanubrutinib" (6 trials) and "Cyclophosphamide" (5 trials). Other intervention names were less common.

The vast majority of trials in "Peking University People's Hospital" are 413 trials for "All" genders, 54 trials for "Female" genders and 6 trials for "Male" genders.

Currently, there are 196 active trials in "Peking University People's Hospital". 21 are not yet recruiting, 123 are recruiting, 45 are Active, not recruiting, and 7 are Enrolling by invitation. In total, there were 162 completed trials in Peking University People's Hospital, 2 suspended trials, and 11 terminated clinical trials to date.

Out of the total trials that were conducted in Peking University People's Hospital, 39 "Phase 1" clinical trials were conducted, 94 "Phase 2" clinical trials and 127 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 46 trials, and there were also 88 trials that are defined as “Not Applicable".

Peking University People's Hospital has several departments that took part in Clinical trials: "Department of Rheumatology and Immunology, Peking University People's Hospital" - 12 trials, "Department of Anesthesiology and Critical Care Medicine, Peking University First Hospital" - 11 trials, "Division of Cardiology, Peking University First Hospital" - 8 trials, "Department of infectious disease, First Hospital of Peking University" - 8 trials, "Musculoskeletal Tumor Center of Peking University People's Hospital" - 5 trials, "Department of Ultrasound Diagnosis, Peking University Third Hospital" - 5 trials, "Peking University Institute of Hematology" - 29 trials, "Breast Center, Peking University People's Hospital" - 2 trials, "Hepatitis Institute of Peking University People's Hospital" - 2 trials